These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 17882685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Estrogen with and without progestin: benefits and risks of short-term use.
    LaCroix AZ.
    Am J Med; 2005 Dec 19; 118 Suppl 12B():79-87. PubMed ID: 16414331
    [Abstract] [Full Text] [Related]

  • 9. Clinical pharmacology and differential cognitive efficacy of estrogen preparations.
    Gleason CE, Carlsson CM, Johnson S, Atwood C, Asthana S.
    Ann N Y Acad Sci; 2005 Jun 19; 1052():93-115. PubMed ID: 16024754
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG, Herrington DM.
    Climacteric; 2005 Dec 19; 8(4):317-26. PubMed ID: 16390766
    [Abstract] [Full Text] [Related]

  • 13. Future long-term trials of postmenopausal hormone replacement therapy - what is possible and what is the optimal protocol and regimen?
    Purbrick B, Stranks K, Sum C, MacLennan AH.
    Climacteric; 2012 Jun 19; 15(3):288-93. PubMed ID: 22612617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK, Governale LA.
    Pharmacoepidemiol Drug Saf; 2005 Mar 19; 14(3):171-6. PubMed ID: 15386701
    [Abstract] [Full Text] [Related]

  • 16. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
    Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS.
    Int J Fertil Womens Med; 2007 Mar 19; 52(2-3):93-6. PubMed ID: 18320867
    [Abstract] [Full Text] [Related]

  • 17. Local and systemic options for hormone replacement therapy.
    Gilliam ML.
    Int J Fertil Womens Med; 2001 Mar 19; 46(4):222-7. PubMed ID: 11563833
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.
    Liu JH.
    Am J Med; 2005 Dec 19; 118 Suppl 12B():88-92. PubMed ID: 16414332
    [Abstract] [Full Text] [Related]

  • 20. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV, Khalil RA.
    Expert Rev Cardiovasc Ther; 2007 Jul 19; 5(4):777-89. PubMed ID: 17605655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.